A. Iancu *
* Dr. Adrian Iancu, director medical, Reprezentanța Novo Nordisk A/S, Romania
Abstract
The type 2 diabetes has two mains underlying pathological conditions: impaired insulin secretion during meals and insulin resistance, both causing hyperglycaemia. There is good evidence linking the postprandial hyperglycaemia with risk of progression of diabetes and of the development of vascular complications. Prandial Glucose Regulation is a new therapeutical concept aiming to restore the normal, diurnal meal related insulin secretion pattern, without stimulating the insulin secretion during the “postabsorbtive” phase. Repaglinide is a new chemical entity, the first β-cell mediated prandial glucose regulator, to be used in the treatment of type 2 diabetes.